



# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. RAMESH CHAND

AGE/ GENDER : 58 YRS/MALE **PATIENT ID** : 1311837

**COLLECTED BY** REG. NO./LAB NO. : 122412130001

REFERRED BY **REGISTRATION DATE** : 13/Dec/2024 08:20 AM BARCODE NO. : 12506128 **COLLECTION DATE** : 13/Dec/2024 08:52AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Dec/2024 10:20AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

### **HAEMATOLOGY HAEMOGLOBIN (HB)**

14.8 HAEMOGLOBIN (HB) 12.0 - 17.0 gm/dL

by CALORIMETRIC

**INTERPRETATION:-**Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.

A low hemoglobin level is referred to as ANEMIA or low red blood count.

#### ANEMIA (DECRESED HAEMOGLOBIN):

- 1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)
- 2) Nutritional deficiency (iron, vitamin B12, folate)
- 3) Bone marrow problems (replacement of bone marrow by cancer)
- 4) Suppression by red blood cell synthesis by chemotherapy drugs
- 5) Kidney failure
- 6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia).

#### POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. RAMESH CHAND

AGE/ GENDER : 58 YRS/MALE **PATIENT ID** : 1311837

**COLLECTED BY** REG. NO./LAB NO. : 122412130001

REFERRED BY **REGISTRATION DATE** : 13/Dec/2024 08:20 AM BARCODE NO. **COLLECTION DATE** : 13/Dec/2024 08:52AM : 12506128 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Dec/2024 10:05AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Test Name Biological Reference interval** 

#### CLINICAL CHEMISTRY/BIOCHEMISTRY

**LIPID PROFILE: BASIC** 

CHOLESTEROL TOTAL: SERUM OPTIMAL: < 200.0  $207.04^{H}$ mg/dL

by CHOLESTEROL OXIDASE PAP BORDERLINE HIGH: 200.0 -

239.0

HIGH CHOLESTEROL: > OR =

240.0

TRIGLYCERIDES: SERUM OPTIMAL: < 150.0 163.84<sup>H</sup> mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) BORDERLINE HIGH: 150.0 -

199.0

HIGH: 200.0 - 499.0

VERY HIGH: > OR = 500.0HDL CHOLESTEROL (DIRECT): SERUM LOW HDL: < 30.0 41.51

mg/dL

by SELECTIVE INHIBITION BORDERLINE HIGH HDL: 30.0 -

60.0

 $HIGH\ HDL: > OR = 60.0$ LDL CHOLESTEROL: SERUM OPTIMAL: < 100.0 132.76<sup>H</sup> mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 -

HIGH: 160.0 - 189.0

VERY HIGH: > OR = 190.0NON HDL CHOLESTEROL: SERUM 165.53<sup>H</sup> mg/dL OPTIMAL: < 130.0

ABOVE OPTIMAL: 130.0 - 159.0

BORDERLINE HIGH: 160.0 -

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

mg/dL VLDL CHOLESTEROL: SERUM 32.77 0.00 - 45.00

by CALCULATED. SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM 577.92 350.00 - 700.00 mg/dL by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM RATIO LOW RISK: 3.30 - 4.40 4.99H by CALCULATED, SPECTROPHOTOMETRY

AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



by CALCULATED, SPECTROPHOTOMETRY





# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. RAMESH CHAND

AGE/ GENDER : 58 YRS/MALE **PATIENT ID** : 1311837

**COLLECTED BY** REG. NO./LAB NO. : 122412130001

REFERRED BY **REGISTRATION DATE** : 13/Dec/2024 08:20 AM BARCODE NO. **COLLECTION DATE** : 13/Dec/2024 08:52AM : 12506128 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Dec/2024 10:05AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM	n all	DATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
by CALCULATED, SPECTROPHOTOMETRY	3.2 <sup>H</sup>	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.95	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)